Dados do Trabalho
Título
ADVERSE REACTIONS TO COVID-19 VACCINES IN PATIENTS WITH DEMYELINATING DISEASES
Resumo
Introduction: Vaccine efficacy is heterogeneous and can be modified by multiple external factors; it is noteworthy that, although vaccines have demonstrated high efficacy or effectiveness in preventing hospitalizations and deaths, all of them have some adverse event. Objectives: To analyze the occurrence of adverse reactions to COVID-19 vaccines in patients with demyelinating diseases. Methods: A retrospective, cross-sectional study carried out by reviewing the medical records of 115 patients, selected in a non-probabilistic manner and for convenience, with demyelinating diseases at the Multiple Sclerosis Reference Center of the State of Paraíba, using the variables sex, age, diagnosis, COVID-19 vaccination, and adverse reactions after COVID-19 vaccination. Results: Among the 115 medical records analyzed, there was a predominance of females (70.43%), in addition, a distribution of 101 (87.82%) patients with Multiple Sclerosis (MS) and 14 (12.12%) with Neuromyelitis Optica (NMO). In categorization by age group, 3% belonged to the age group under 16 years old, 9% from 16 to 25 years old, 34% from 26 to 35 years old, 31% from 36 to 45 years old; 10% from 46 to 55 years old; 10% from 56 to 65 years old and 3% from those over 65 years old. Regarding the vaccination of COVID-19, 100% performed the first dose, 99% the second dose and 74% the third dose. Regarding vaccine reactions, reactions were reported in 49% of patients, with 36% reporting body pain, 30% pain at the injection site, 16% fever, 16% headache, 11% chills, 9% worsening of MS symptoms, 5% fatigue, 4% nausea, 2% vomiting and diarrhea. Among the patients who had vaccine reactions, 11% had NMO and 89% had MS. Conclusion: The effectiveness of vaccination varies according to the vaccine applied, and may present vaccine reactions, despite being extremely effective in preventing deaths resulting from infection by SARS-CoV-2. We can observe that no patient had serious adverse reactions. Thus, vaccination against Sars-COV 2 is extremely important, since the benefits will be greater than the harm, as observed in the study.
Palavras Chave
COVID-19. VACCINES. MULTIPLE SCLEROSIS. NEUROMYELITIS OPTICA. DEMYELINATING DISEASES
Área
Neuroimunologia
Autores
Jairo Aragão Perez, Antonio Marcelo Rodrigues Moreira Filho, Fernando de Paiva Melo Neto, Luis Felipe Dantas da Nóbrega Machado, Milton Paulo Cabral de Melo Pinto, Nivaldo Alves Calado Neto, Davi Veloso Guerra, Bianca Etelvina Santos de Oliveira